STTR Phase I: On-chip integration of sample preparation and monitoring with dielectrophoretic cell isolation

STTR 第一阶段：样品制备和监测与介电泳细胞分离的片上集成

• 批准号: 2051652
• 负责人: Alexandra Hyler
• 金额: $ 25.6万
• 依托单位: CYTORECOVERY, INC.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-03-15 至 2022-02-28
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2051652&HistoricalAwards=false
• 关键词: STTR; Phase; chip; integration; sample

The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project is a platform to isolate cells based on their biophysical properties. The platform will help isolate cells that are not abundant and enable study of their role in biological function and diseases such as cancer. Specifically, a single chip platform will carry out sample preparation, manipulation, and monitoring, greatly reducing the sample handling steps and thereby ensuring the maintenance of cell viability and improvement in sample consistency. This recovered sample is essential for the development of cell-based therapies in regenerative medicine and cancer management.This Small Business Technology Transfer (STTR) Phase I project will develop an electrically functional microfluidic sample manipulation platform for phenotype-selective recovery of cells, based on their biophysical attributes that allow discrimination between distinct electrophysiological properties for the cells of interest within the sample media. Specifically, microfluidic designs will be developed to swap cells from complex biological matrices into an optimized buffer for enabling cell manipulation, and the instrumentation will be developed for on-chip monitoring of the sample during various stages of the phenotype-selective cell recovery process. The designs will be optimized for enhanced levels of selection purity, while maintaining high cell collection efficiencies, so that the recovered sample is enriched for cell phenotypes of interest.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这个小企业技术转让（STTR）第一阶段项目的更广泛的影响/商业潜力是一个基于细胞生物物理特性分离细胞的平台。该平台将有助于分离不丰富的细胞，并研究它们在生物功能和癌症等疾病中的作用。具体而言，单芯片平台将进行样品制备、操作和监测，大大减少了样品处理步骤，从而确保细胞活力的维持和样品一致性的提高。这一回收的样品对于再生医学和癌症管理中基于细胞的疗法的开发至关重要。这一小企业技术转让（STTR）第一阶段项目将开发一种电功能微流体样品操作平台，用于细胞的表型选择性回收，基于其生物物理属性，允许区分样品介质中感兴趣细胞的不同电生理特性。具体而言，将开发微流体设计以将细胞从复杂的生物基质交换到优化的缓冲液中，以实现细胞操作，并且将开发仪器用于在表型选择性细胞回收过程的各个阶段期间对样品进行芯片上监测。该设计将进行优化，以提高选择纯度，同时保持高细胞收集效率，使回收的样品富集感兴趣的细胞表型。该奖项反映了NSF的法定使命，并已被认为是值得通过使用基金会的智力价值和更广泛的影响审查标准进行评估的支持。